Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

371
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
371
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

585
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
585
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

349
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
349
Electrical Current01:10

Electrical Current

7.2K
Electrical current is defined as the rate at which charge flows. When there is a large current present, such as that used to run a refrigerator, a large amount of charge moves through the wire in a small amount of time. If the current is small, such as that used to operate a handheld calculator, a small amount of charge moves through the circuit over a long period of time. The SI unit for current is the ampere (A), named for the French physicist André-Marie Ampère (1775–1836).
7.2K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

635
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
635
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

614
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
614

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Transcranial ultrasound stimulation of motor networks in Parkinson's disease informed by local field potential dynamics.

Science translational medicine·2026
Same author

Depressive symptoms, but not OSA severity, are associated with general fatigue in myasthenia gravis.

Sleep medicine·2026
Same author

Association between statin use and survival in patients with ALS: A propensity score-matched analysis.

Journal of the neurological sciences·2026
Same author

The Muscle Cramp Impact Index: A Patient-Centered Scale for the Assessment of Muscle Cramps.

Neurology·2026
Same author

Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis.

Nature genetics·2026
Same author

Neuropsychiatric Symptom Clusters and Their Association With Brain Structure in Alzheimer Disease.

The Journal of clinical psychiatry·2026
Same journal

IgG Subclass (IgG1-4) and IgA Autoantibody Profiles Against Muscle-Specific Kinase in a Greek Cohort.

Muscle & nerve·2026
Same journal

Mindfulness for Myasthenia Gravis.

Muscle & nerve·2026
Same journal

Cure in Myasthenia Gravis: An Unmet Need.

Muscle & nerve·2026
Same journal

Treatment Preferences of Patients With Myasthenia Gravis: A Qualitative Study.

Muscle & nerve·2026
Same journal

At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial.

Muscle & nerve·2026
Same journal

The Use of the Four Square Step Test and the 10-m Walk/Run Test to Determine Fall Risk in Children With Duchenne Muscular Dystrophy.

Muscle & nerve·2026
関連記事をすべて見る

関連する実験動画

Updated: Feb 8, 2026

Simultaneous EEG Monitoring During Transcranial Direct Current Stimulation
07:52

Simultaneous EEG Monitoring During Transcranial Direct Current Stimulation

Published on: June 17, 2013

40.4K

現在の進行中の臨床研究

Agessandro Abrahao1, Lorne Zinman1, Stephen Apple2

  • 1Division of Neurology, Department of Medicine and Harquail Centre for Neuromodulation, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Muscle & nerve
|February 7, 2026
PubMed
まとめ
この要約は機械生成です。

進行中の研究では、筋萎縮性側索硬化症（ALS）治療におけるエダラボン（静脈内投与および経口懸濁液）を評価しています。研究は、エダラボンを主要なALS治療選択肢として支持するために、有効性、安全性、および生物学的影響を明らかにすることを目指しています。

キーワード:
ALS筋萎縮性側索硬化症臨床臨床試験エダラボン

さらに関連する動画

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.1K
Transcranial Direct Current Stimulation tDCS for Memory Enhancement
10:37

Transcranial Direct Current Stimulation tDCS for Memory Enhancement

Published on: September 18, 2021

15.8K

関連する実験動画

Last Updated: Feb 8, 2026

Simultaneous EEG Monitoring During Transcranial Direct Current Stimulation
07:52

Simultaneous EEG Monitoring During Transcranial Direct Current Stimulation

Published on: June 17, 2013

40.4K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.1K
Transcranial Direct Current Stimulation tDCS for Memory Enhancement
10:37

Transcranial Direct Current Stimulation tDCS for Memory Enhancement

Published on: September 18, 2021

15.8K

科学分野:

  • 神経学
  • 薬理学
  • 臨床研究

背景:

  • 筋萎縮性側索硬化症（ALS）は、治療選択肢が限られている進行性の神経変性疾患です。
  • 静脈内（IV）および経口懸濁液として利用可能なエダラボンは、ALSの新たな治療薬です。
  • エダラボン​​の完全な臨床的有用性を理解するには、多様な研究設定での継続的な評価が必要です。

研究 の 目的:

  • ALS治療のためのエダラボンに関する現在および計画中の研究の包括的な概要を提供すること。
  • 様々な臨床的文脈におけるエダラボン​​の有効性、安全性、および生物学的メカニズムを評価すること。
  • ALSの最適な治療戦略と将来の治療アプローチを知らせること。

主な方法:

  • 進行中および完了した臨床試験および観察研究のレビュー。
  • 市販後調査および自然歴レジストリからのデータの分析。
  • エダラボン​​の病態生理学的影響を探るためのバイオマーカーデータの含​​入。

主要な成果:

  • 複数の研究で、静脈内投与エダラボンと経口エダラボン懸濁液の両方が評価されています。
  • 進行中の研究には、長期サーベイランス、自然歴追跡、バイオマーカー分析が含まれます。
  • 臨床試験は、エダラボン製剤の安全性、忍容性、有効性を支持しています。

結論:

  • 現在および進行中の研究は、ALSの貴重な治療選択肢としてエダラボン​​を総合的に支持しています。
  • エダラボン​​治療の改善には、臨床試験および実臨床からの継続的なデータ収集が不可欠です。
  • これらの取り組みは、進化するALSの状況における最適な戦略と併用療法を導くでしょう。